• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Fortrea Holdings Inc.

    8/31/25 7:33:24 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    S-8 1 forms-8arplan.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 29, 2025
    Registration No. 333-          
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    _______________________________
    FORM S-8
    Registration Statement
    Under
    the Securities Act of 1933
    _______________________________
    Fortrea Holdings Inc.
    (Exact name of registrant as specified in its charter)
    _______________________________
    Delaware92-2796441
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    8 Moore Drive
    Durham, North Carolina 27709
    (Address of Principal Executive Offices)
    27709
    (Zip Code)
    Fortrea Holdings Inc. 2023 Omnibus Incentive Plan, as Amended and Restated
    (Full title of the plans)
    Stillman Hanson
    General Counsel
    Fortrea Holdings Inc.
    8 Moore Drive
    Durham, North Carolina 27709
    (Name and address of agent for service)
    +1 (877) 495-0816
    (Telephone number, including area code, of agent for service)
    With a copy to:
    Amy M. Batten, Esq.
    Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
    150 Fayetteville Street, Suite 2300
    Raleigh, NC 27601
    (919) 821-1220
    _______________________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filerAccelerated filer
    Non-accelerated filer
    Smaller reporting company
    Emerging growth company
    _______________________________
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    _______________________________




    STATEMENT OF INCORPORATION BY REFERENCE

    This Registration Statement on Form S-8 is being filed by Fortrea Holdings Inc. (the “Company”) to register an additional 6,500,000 shares of the Common Stock of the Company, $0.001 par value per share (the “Common Stock”), issuable under the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan, as amended and restated (the “A&R Plan”).

    Pursuant to General Instruction E of Form S-8, except for Item 3 “Incorporation of Documents by Reference,” Item 5 “Interests of Named Experts and Counsel” and Item 8 “Exhibits,” the prior Registration Statement relating to the A&R Plan, Registration No. 333-273037 filed with the Securities and Exchange Commission (the “Commission”) on June 29, 2023, remains effective, and the contents of such prior Registration Statement is incorporated in this Registration Statement by reference. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The Commission allows us to “incorporate by reference” the information the Company files with the Commission, which means that the Company can disclose important information by referring to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the Commission will update and supersede this information. The Company hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (a)The Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 3, 2025;
    (b)The Company’s Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, filed with the Commission on May 12, 2025, and June 30, 2025, filed with the Commission on August 6, 2025, respectively;
    (c)The Company’s Current Reports on Form 8-K filed with the Commission on February 21, 2025, March 10, 2025, May 12, 2025, May 15, 2025, June 11, 2025, June 12, 2025, June 12, 2025, and August 27, 2025;
    (d)The description of the Company’s Common Stock contained in the information statement filed as Exhibit 99.1 to Amendment No. 2 to the Company’s registration statement on Form 10 filed on June 8, 2023 (File No. 001-41704), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.4 to the Company’s Annual Report of Form 10-K for the year ended December 31, 2024, filed with the Commission on March 3, 2025.

    In addition, all documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    The Company is not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL




    The validity of the securities being registered by this Registration Statement will be passed upon for the Company by Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P., Raleigh, North Carolina

    ITEM 8. EXHIBITS
    The exhibits below are filed or furnished as a part of this report and are incorporated herein by reference.

    INCORPORATED BY REFERENCE
    EXHIBIT NO.DESCRIPTIONFiled HerewithFORMFile No.ExhibitFiling Date
    4.1
    Amended and Restated Certificate of Incorporation of Fortrea Holdings Inc.
    8-K001-417043.13-Jul-23
    4.2
    Certificate of Designations of Series A Preferred Stock of Fortrea Holdings Inc., as filed with the Secretary of State of the State of Delaware on June 12, 2025.
    8-K001-417043.112-Jun-25
    4.3
    Rights Agreement, dated as of June 11, 2025 between Fortrea Holdings Inc. and Equiniti Trust Company, LLC, as rights agent.
    8-K001-417044.112-Jun-25
    4.4
    Amended and Restated By-Laws of Fortrea Holdings Inc
    8-K001-417043.23-Jul-23
    5.1
    Opinion of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
    X
    23.1
    Consent of Deloitte & Touche, an independent registered accounting firm.
    X
    23.2
    Consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. (included in Exhibit 5.1).
    X
    24.1Powers of Attorney (included on the signature page of the Registration Statement).X
    99.1
    Fortrea Holdings Inc. 2023 Omnibus Incentive Plan (as amended and restated).
    10-Q001-4170410.56-Aug-25
    107
    Filing Fee Table
    X




    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on August 29, 2025.

    FORTREA HOLDINGS INC.
    By:/s/ Anshul Thakral
    Name: Anshul Thakral
    Title: President, Chief Executive Officer and Director

    POWER OF ATTORNEY
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on August 29, 2025, each person whose signature appears below appoints Anshul Thakral, Stillman Hanson and Jill McConnell, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any additional registration statement (including any amendment thereto) for this offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    SignatureTitle
    /s/ Anshul ThakralPresident, Chief Executive Officer and Director
    (Principal Executive Officer)
    Anshul Thakral
    /s/ Jill McConnellChief Financial Officer
    (Principal Financial Officer)
    Jill McConnell
    /s/ Robert A. ParksChief Accounting Officer
    Robert A. Parks(Principal Accounting Officer)
    /s/ Peter NeupertChairman of the Board of Directors
    Peter Neupert
    /s/ Edward PesickaDirector
    Edward Pesicka
    /s/ Dr. Amrit RayDirector
    Dr. Amrit Ray
    /s/ Erin L. RussellDirector
    Erin L. Russell
    /s/ Machelle SandersDirector
    Machelle Sanders
    /s/ David SmithDirector
    David Smith

    Get the next $FTRE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    7/24/2024$30.00Equal Weight
    Barclays
    More analyst ratings

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Reports Second Quarter 2025 Results

    For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $54.9 millionGAAP and adjusted net (loss) income per diluted share of $(4.14) and $0.19, respectivelyBook-to-bill ratio of 0.79x, resulting in 1.10x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,600 million to $2,700 million; affirming 2025 adjusted EBITDA guidance DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today rep

    8/6/25 6:30:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement awards to Anshul Thakral, the Company's recently appointed President and Chief Executive Officer, as an inducement material to Mr. Thakral becoming a new employee of the Company. The grants were previously approved by the independent members of the Company's Board of Directors and were made in connection with Mr. Thakral's start date with the Company on August 4, 2025 (the "Effective Date"). The awards consisted of (i) 1,250,000 performance share units ("PSUs") that will vest, if at all,

    8/4/25 4:30:41 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Parks Robert converted options into 2,042 shares and sold $6,056 worth of shares (592 units at $10.23) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/10/25 4:36:55 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. converted options into 5,788 shares and sold $17,156 worth of shares (1,677 units at $10.23), increasing direct ownership by 27% to 19,092 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/10/25 4:34:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Operating Officer Morais Mark A. converted options into 7,156 shares and sold $32,276 worth of shares (3,155 units at $10.23), increasing direct ownership by 8% to 56,976 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/10/25 4:32:34 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $FTRE
    SEC Filings

    View All

    Fortrea upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Fortrea from Neutral to Outperform and set a new price target of $9.00

    8/4/25 8:16:07 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Truist initiated coverage on Fortrea with a new price target

    Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

    5/2/25 8:14:26 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea downgraded by Barclays with a new price target

    Barclays downgraded Fortrea from Equal Weight to Underweight and set a new price target of $6.00

    4/10/25 8:49:08 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    9/9/25 4:44:52 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    9/9/25 4:44:22 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Fortrea Holdings Inc.

    S-8 - Fortrea Holdings Inc. (0001965040) (Filer)

    8/31/25 7:33:24 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

    DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

    2/20/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

    SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

    12/5/24 4:05:00 PM ET
    $BDX
    $FTRE
    $MRVI
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports Second Quarter 2025 Results

    For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $54.9 millionGAAP and adjusted net (loss) income per diluted share of $(4.14) and $0.19, respectivelyBook-to-bill ratio of 0.79x, resulting in 1.10x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,600 million to $2,700 million; affirming 2025 adjusted EBITDA guidance DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today rep

    8/6/25 6:30:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call

    DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webca

    7/16/25 7:00:47 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Adopts Limited-Duration Stockholder Rights Plan

    DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that its Board of Directors (the "Board") has unanimously adopted a limited-duration stockholder rights plan ("Rights Plan") to protect the best interests of all Fortrea stockholders. The Rights Plan is effective immediately and will expire on June 10, 2026, unless terminated earlier by the Board. The Rights Plan is intended to enable the Company's stockholders to realize the long-term value of their investment, ensure that all stockholders receive fair and equal treatment in the event of any proposed takeover of the Company, and to

    6/12/25 8:36:04 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care